UnitedHealth Group has long commanded a valuation premium based on its industry-leading scale and stable cash flows, but over the past year the stock’s total return has underperformed key peers by more than 10 percentage points. Market participants are scrutinizing the sustainability of UnitedHealth’s growth drivers—namely Medicare Advantage enrollment and Optum margin expansion—as its forward price-to-earnings multiple has contracted from the mid-20s to the low-20s. Investors are weighing whether near-term headwinds in medical cost trends and regulatory scrutiny of pharmacy benefit management services justify a revaluation of the company’s historically high multiple.

According to the latest Form 13F filings, Lee Financial Co initiated a new position of 3,390 shares valued at approximately $1.17 million in the third quarter. Brighton Jones LLC more than doubled its stake—adding 28,231 shares—to bring its total holding to 44,249 shares, representing a commitment of $22.38 million. Revolve Wealth Partners LLC grew its allocation by 137.1%, acquiring an additional 2,324 shares at a cost of $2.03 million, while CMT Capital Markets Trading GmbH and Patriot Financial Group Insurance Agency LLC established stakes valued at $340,000 and $1.66 million, respectively. Overall, nearly 88% of UnitedHealth shares remain in institutional hands, underscoring continued confidence among professional money managers.

In the fourth-quarter earnings release, UnitedHealth reported adjusted earnings per share of $2.11, narrowly exceeding consensus expectations by $0.02, with revenue rising 12.3% year-over-year to $113.22 billion. The company’s net margin of 2.69% reflected ongoing investments in care delivery and technology. Management reiterated full-year guidance for adjusted EPS in a range implying mid-teens percentage growth, supported by projected Medicare Advantage membership gains and Optum’s expanding services pipeline. Analysts have responded by adjusting their models—one shop trimmed its EPS forecast by 8% while another raised its outlook by 2%—resulting in a consensus estimate of 29.54 EPS for the current fiscal year.

UnitedHealth declared its quarterly dividend of $2.21 per share for shareholders of record as of December 8, translating into an annualized payout of $8.84 and a yield of approximately 3.1%. The company’s dividend payout ratio stands at 67%, reflecting a commitment to returning cash to investors while retaining flexibility to fund acquisitions and share repurchases. This combination of modest payout growth and a double-digit return on equity continues to attract income-oriented strategies seeking a balance between yield and growth.